Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

Read an interview with Carl June, MD, a pioneer in CAR T-cell therapy

From the Current Issue

  • Research Articles | Free Article
    Combinatorial ETS1-Dependent Control of Oncogenic NOTCH1 Enhancers in T-cell Leukemia
    Anna C. McCarter, Giusy Della Gatta, Ashley Melnick, Erin Kim, Cher Sha, Qing Wang, Jahnavi K. Nalamolu, Yiran Liu, Theresa M. Keeley, Ran Yan, Mengxi Sun, Rohan Kodgule, Nicholas Kunnath, Alberto Ambesi-Impiombato, Rork Kuick, Arvind Rao, Russell J.H. Ryan, Barbara L. Kee, Linda C. Samuelson, Michael C. Ostrowski, Adolfo A. Ferrando and Mark Y. Chiang
    Blood Cancer Discov September 1 2020 1 (2) 178-197; DOI:10.1158/2643-3230.BCD-20-0026

    Ets1 coregulates Notch transcriptional program in T cells and is essential for Notch-driven T-ALL but not intestinal homeostasis, suggesting its targeting in T-ALL as a less toxic alternative to Notch inhibition.

  • Research Briefs | Free Article
    Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma
    Carlos Fernández de Larrea, Mette Staehr, Andrea V. Lopez, Khong Y. Ng, Yunxin Chen, William D. Godfrey, Terence J. Purdon, Vladimir Ponomarev, Hans-Guido Wendel, Renier J. Brentjens and Eric L. Smith
    Blood Cancer Discov September 1 2020 1 (2) 146-154; DOI:10.1158/2643-3230.BCD-20-0020

    CAR T cells targeting two multiple myeloma (MM) antigens are generated by orthogonal approaches, of which bicistronic vector shows superior activity, conferring long-term resistance against MM in a mouse xenograft model of antigen escape.

  • Research Articles | Free Article
    BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity
    Charles R. Schmidt, Nicholas J. Achille, Aravinda Kuntimaddi, Adam M. Boulton, Benjamin I. Leach, Shubin Zhang, Nancy J. Zeleznik-Le and John H. Bushweller
    Blood Cancer Discov September 1 2020 1 (2) 162-177; DOI:10.1158/2643-3230.BCD-20-0036

    Structure-function characterization of AF9 complexes with BCOR and CBX8 identifies BCOR-Eya1-Myc axis in MLL-AF9-driven leukemogenesis.

  • Research Articles | AuthorChoice
    Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia
    Tian Zhang, Jiawen Yang, Vijaya P. Vaikari, John S. Beckford, Sharon Wu, Mojtaba Akhtari and Houda Alachkar
    Blood Cancer Discov September 1 2020 1 (2) 198-213; DOI:10.1158/2643-3230.BCD-19-0077

    Elevated APOC2 expression correlates with MLL-rearrangement and worse prognosis in AML. APOC2 promotes AML growth through CD36-dependent lipid metabolism, and blocking APOC2 or CD36 slows down AML progression in mice.

  • Research Briefs | Free Article
    Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma
    Stefania Pittaluga, Alina Nicolae, George W. Wright, Christopher Melani, Mark Roschewski, Seth Steinberg, DaWei Huang, Louis M. Staudt, Elaine S. Jaffe and Wyndham H. Wilson
    Blood Cancer Discov September 1 2020 1 (2) 155-161; DOI:10.1158/2643-3230.BCD-20-0009

    Transcriptiomic and clinico-pathologocal comparison of mediastinal gray zone lymphoma to related disorders documents intrinsic heterogeneity and refines features relevant to diagnosis and therapy.


OnlineFirst Articles

Load more
Advertisement

Back to top